Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028307 | 1.00 | PTGS1 (0.34) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL7360975 | 1.00 | PTGS1 (0.34) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL38660143 | 0.85 | KDM4E (0.36) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL3230289 | 0.85 | KDM4E (0.36) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL7646334 | 0.85 | KDM4E (0.36) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL8276211 | 0.82 | ALDH1A1 (0.33) | ALDH1A1LMNAPOLBHSD17B10L3MBTL1 | |
| SCHEMBL4632069 | 0.79 | PTGS1 (0.47) | PTGS1SLC7A11ENPEP | |
| SCHEMBL3858823 | 0.78 | TDP1 (0.37) | MAPTSMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL11109011 | 0.77 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL20512314 | 0.77 | PTGS1 (0.37) | PTGS1SLC7A11KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1106657-A | Pharmaceutical composition for maintaining and/or reestablishing a near normal blood platelet aggregarion rate | MARTHE DEHORNE (FR) | 1995-08-16 | — | — | CN | claimed |
| EP-0645138-A2 | Pharmaceutical composition for maintaining and/or reestablishing a rate of blood platelet aggregation clone to the normal value | Dehorne, Marthe (FR) | 1995-03-29 | — | — | EP | claimed |
| EP-0483261-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1992-05-06 | — | — | EP | claimed |
| WO-1991001328-A1 | HIRUDIN PEPTIDE DERIVATIVES | BIOGEN, INC. (US) | 1991-02-07 | — | — | WO | claimed |
| EP-3146977-B1 | TFPI INHIBITORS AND METHODS OF USE | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-11793855-B2 | TFPI inhibitors and methods of use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-10800816-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2020-10-13 | — | — | US | disclosed |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-09 | — | — | US | disclosed |
| EP-2827883-B1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10201586-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2019-02-12 | — | — | US | disclosed |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | Baxalta GmbH (CH) | 2018-06-07 | — | — | US | disclosed |
| US-9873720-B2 | TFPI inhibitors and methods of use | Baxalta GmbH (CH) | 2018-01-23 | — | — | US | disclosed |
| US-8450275-B2 | TFPI inhibitors and methods of use | BAXTER INTERNATIONAL INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | BAXTER INTERNATIONAL INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-0975321-A2 | THE USE OF THIOGLYCOLIC ACID AS DEPIGMENTING AGENT | I.V. Pharma S.A.S. (IT) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047466-A2 | THE USE OF THIOGLYCOLIC ACID AS DEPIGMENTING AGENT | I.V. PHARMA S.A.S. (IT) | 1998-10-29 | — | — | WO | disclosed |
| CN-1106657-A | Pharmaceutical composition for maintaining and/or reestablishing a near normal blood platelet aggregarion rate | MARTHE DEHORNE (FR) | 1995-08-16 | — | — | CN | disclosed |
| EP-0645138-A2 | Pharmaceutical composition for maintaining and/or reestablishing a rate of blood platelet aggregation clone to the normal value | Dehorne, Marthe (FR) | 1995-03-29 | — | — | EP | disclosed |
| EP-0440633-A1 | PHARMACEUTICAL FOR TREATING TUMORS IN HUMANS AND METHOD FOR MAKING IT. | ALFACELL CORP (US) | 1991-08-14 | — | — | EP | disclosed |
| WO-1989009606-A1 | PHARMACEUTICAL FOR TREATING TUMORS IN HUMANS AND METHOD FOR MAKING IT | ALFACELL CORPORATION (US) | 1989-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028901-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | PTGS1 1204/4885SLC7A11 3554/4885KDM4E 4344/4885 |
| US-20180155399-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F13B | PTGS1 1153/4885SLC7A11 3386/4885KDM4E 4610/4885 |
| US-10201586-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | PTGS1 1270/4885SLC7A11 3513/4885KDM4E 4324/4885 |
| US-11793855-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F3 | PTGS1 1270/4885SLC7A11 3513/4885KDM4E 4324/4885 |
| US-10800816-B2 | TFPI inhibitors and methods of use | TFPI, TFPI2, F13B | PTGS1 1153/4885SLC7A11 3386/4885KDM4E 4610/4885 |
| US-20190134147-A1 | TFPI INHIBITORS AND METHODS OF USE | TFPI, TFPI2, F3 | PTGS1 1270/4885SLC7A11 3513/4885KDM4E 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.